Prognostic role of the pre-treatment platelet-lymphocyte ratio in pancreatic cancer : a meta-analysis
BACKGROUND AND AIMS: Recently, the pre-treatment platelet-lymphocyte ratio (PLR), which is based on blood parameters, was accepted as a prognostic factor for patients with various cancers. Numerous studies have investigated the prognostic role of the PLR in pancreatic cancer; however, it remains unclear. Therefore, we conducted this meta-analysis to evaluate the relationship between the pre-treatment PLR and overall survival (OS) in pancreatic cancer.
MATERIALS AND METHODS: We performed a systematic literature search of the PubMed, Embase and Web of Science databases for relevant studies that explored the prognostic role of the pre-treatment PLR in pancreatic cancer. The hazard ratios (HRs) and 95% confidence intervals (CIs) related to OS were pooled using a random effects model.
RESULTS: Fourteen retrospective cohort studies involving 2,260 patients were included in this meta-analysis. Compared with low PLR, high PLR was a predictor of shorter OS (HR = 1.24, 95% CI: 1.10-1.39, I2 = 74%).
CONCLUSIONS: In this meta-analysis, high pre-treatment PLR was a bio-predictor of short OS in patients with pancreatic cancer, suggesting that PLR could be used to predict prognosis of patients with pancreatic cancer before treatment. However, additional well-designed and large-scale studies are necessary.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Oncotarget - 8(2017), 58 vom: 17. Nov., Seite 99003-99012 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xu, Zheng-Shui [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Revised 14.03.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.18632/oncotarget.20871 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM278935893 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM278935893 | ||
| 003 | DE-627 | ||
| 005 | 20231225021801.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.20871 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0929.xml |
| 035 | |a (DE-627)NLM278935893 | ||
| 035 | |a (NLM)29228745 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xu, Zheng-Shui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic role of the pre-treatment platelet-lymphocyte ratio in pancreatic cancer |b a meta-analysis |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.03.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND AND AIMS: Recently, the pre-treatment platelet-lymphocyte ratio (PLR), which is based on blood parameters, was accepted as a prognostic factor for patients with various cancers. Numerous studies have investigated the prognostic role of the PLR in pancreatic cancer; however, it remains unclear. Therefore, we conducted this meta-analysis to evaluate the relationship between the pre-treatment PLR and overall survival (OS) in pancreatic cancer | ||
| 520 | |a MATERIALS AND METHODS: We performed a systematic literature search of the PubMed, Embase and Web of Science databases for relevant studies that explored the prognostic role of the pre-treatment PLR in pancreatic cancer. The hazard ratios (HRs) and 95% confidence intervals (CIs) related to OS were pooled using a random effects model | ||
| 520 | |a RESULTS: Fourteen retrospective cohort studies involving 2,260 patients were included in this meta-analysis. Compared with low PLR, high PLR was a predictor of shorter OS (HR = 1.24, 95% CI: 1.10-1.39, I2 = 74%) | ||
| 520 | |a CONCLUSIONS: In this meta-analysis, high pre-treatment PLR was a bio-predictor of short OS in patients with pancreatic cancer, suggesting that PLR could be used to predict prognosis of patients with pancreatic cancer before treatment. However, additional well-designed and large-scale studies are necessary | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a PLR | |
| 650 | 4 | |a meta-analysis | |
| 650 | 4 | |a overall survival | |
| 650 | 4 | |a pancreatic cancer | |
| 700 | 1 | |a Zhang, Fa-Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yin |e verfasserin |4 aut | |
| 700 | 1 | |a Ou-Yang, Yong-Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Xiao-Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Wen-Long |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Wen-Ji |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Zhi-Qiang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncotarget |d 2010 |g 8(2017), 58 vom: 17. Nov., Seite 99003-99012 |w (DE-627)NLM199620113 |x 1949-2553 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2017 |g number:58 |g day:17 |g month:11 |g pages:99003-99012 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.20871 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2017 |e 58 |b 17 |c 11 |h 99003-99012 | ||